Bristol Myers turns to Oxford Biomedica for CAR-T manufacturing

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/tadamichi)
(Image: Getty/tadamichi)

Related tags: Bristol Myers Squibb, Bristol-myers squibb, CAR-T

Oxford Biomedica set to receive up to $96m to support the development of Juno’s CAR-T therapies.

The agreement will see Oxford Biomedica partner with Juno Therapeutics, a chimeric antigen receptor (CAR)-T therapy developer, acquired​ in 2018 by Celgene, which is, in turn, now a Bristol Myers Squibb company​.

Under a non-exclusive license, Oxford Biomedica will provide Juno with access to its LentiVector platform, supporting the development of the latter’s CAR-T and T cell receptor therapeutics (TCR-T) programs.

Moreover, the companies have agreed to a five-year long clinical supply of lentiviral vectors for Juno’s development projects, with the potential for further extension of the agreement.

Per the financial terms, Oxford Biomedica will receive an upfront cash payment of $10m (€9.3m); up to $86m (€80.1m) dependent on development and regulatory milestones; and up to $131m (€122.1m) in sales-based milestone payments.

The manufacturing work has begun at Oxford Biomedica's commercial manufacturing center located in Oxford, UK, with the manufacturer working on four undisclosed projects.

Juno and BMS are putting significant efforts​ into optimizing manufacturing for CAR-T development projects, since a potential approval would see any product arrive as the third to market, after the commercialization of Novartis’ Kymriah (tisagenlecleucel), and Gilead’s Yescarta (axicabtagene ciloleucel).

In December 2019, BMS won a patent infringement suit​ against Gilead on Yescarta, which saw the latter’s subsidiary, Kite, ordered to pay Juno $752m – though Juno then requested the judge to raise that penalty to $1.5bn.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars